Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma.

ABSTRACT:

Background

Prognostic biomarkers for osteosarcoma (OS) at the time of diagnosis are lacking. Necrotic response of OS to preoperative chemotherapy correlates with survival and is determined 3-4 months after diagnosis. The purpose of this study is to identify biomarkers that will stratify patients into good or poor responders to chemotherapy at diagnosis and determine the role of potential biomarkers in OS pathogenesis.

Procedure

Because OS may be caused by disruptions of osteogenic differentiation, and the Notch pathway is one regulator of bone development, we examined the link between Notch effectors, OS differentiation, and OS outcome. We probed the R2: Genomics Analysis and Visualization Platform for RNA expression levels of Notch targets in mixed high-grade OS pretreatmen

SUBMITTER: McManus M 

PROVIDER: S-EPMC6240354 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature